A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.

Trial Details

NCT ID
NCT07229313
Phase
PHASE1
Sponsor
Kivu Bioscience Inc.
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • KIVU-107
Locations (sample)
  • Santa Monica, California, United States|34.01949,-118.49138
  • Camperdown, New South Wales, Australia|-33.88965,151.17642
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Brisbane, Queensland, Australia|-27.46794,153.02809
  • Adelaide, South Australia, Australia|-34.92866,138.59863

Key Eligibility Criteria

  • Male or female ≥18 years of age
  • No therapy of proven efficacy exists for the tumor
  • Pathologically or histologically documented diagnosis of advanced / metastatic solid tumor malignancy that is resistant to standard therapy or for …
  • Adequate bone marrow, kidney, and liver function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →